William Blair Reaffirms Their Hold Rating on AZEK Company (AZEK)
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
According to TipRanks, Merkel is a 4-star analyst with an average return of 9.2% and a 60.95% success rate. Merkel covers the Industrials sector, focusing on stocks such as Aaon, Beacon Roofing Supply, and Fastenal Company.
AZEK Company has an analyst consensus of Moderate Buy, with a price target consensus of $52.29.
AZEK market cap is currently $7.19B and has a P/E ratio of 49.97.
Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AZEK in relation to earlier this year. Last month, Jesse Singh, the CEO & President of AZEK sold 25,000.00 shares for a total of $1,158,357.93.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
William Blair Remains Bullish on Genmab A/S (GMAB)
Genmab A/S (NASDAQ:GMAB) is one of the top most undervalued biotech stocks to buy now. On August 7, William Blair analyst Matt Phipps reiterated a bullish stance on Genmab A/S (NASDAQ:GMAB), giving the stock a Buy rating without assigning a price target. A scientist in a lab using a microscope to develop new treatments for Multiple Myeloma. The analyst supported the rating with the company's solid financial performance and promising pipeline developments, stating that Genmab A/S (NASDAQ:GMAB) surpassed both consensus and internal revenue estimates, reporting strong fiscal Q2 results. He attributed the growth to a notable sales growth of Epkinly and robust royalties from Darzalex and Kesimpta. The company's financial strength prompted an upward revision of the full-year revenue guidance, suggesting increased confidence in solid performance by Genmab A/S (NASDAQ:GMAB), the analyst added. Genmab A/S (NASDAQ:GMAB) is an international biotechnology company that develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes DARZALEX to treat certain indications of multiple myeloma, TEPEZZA for the treatment of thyroid eye disease, and Arzerra to treat certain indications of chronic lymphocytic leukemia. While we acknowledge the potential of GMAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
a day ago
- Yahoo
William Blair Maintained a Buy Rating on TTEC Holdings (TTEC)
TTEC Holdings, Inc. (NASDAQ:TTEC) is one of the . On August 8, William Blair analyst Maggie Nolan maintained a Buy rating on TTEC Holdings, Inc. (NASDAQ:TTEC), without disclosing any price target. The analyst reiterated his bullish sentiment following the company's fiscal second quarter 2025 earnings release. Nolan noted that the company exceeded revenue expectations despite a slight 3.8% year-over-year decrease. The company posted a revenue of $513.57 million, which exceeded expectations by $17.64 million. Moreover, TTEC Holdings, Inc. (NASDAQ:TTEC) demonstrated solid growth, particularly in its embedded customer base within the Engage segment. The segment showed a decline but outperformed estimates, driven by AI-driven solutions that improved client retention and growth. A business executive reviewing customer analytics on their laptop in a modern office. In addition, Nolan also highlighted the company's cost optimization strategies that led to better operating margins across both its segments. Looking ahead, management raised its full-year outlook and now expects revenue in the range of $2.06 billion to $2.11 billion. TTEC Holdings, Inc. (NASDAQ:TTEC) provides customer experience technology and services, using artificial intelligence. It operates through two main segments, including the Digital and Engage segments. While we acknowledge the potential of TTEC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
William Blair Retains Buy Rating on EPAM Systems Following Q2 FY2025 Results
EPAM Systems, Inc. (NYSE:EPAM) is one of the Best Affordable AI Stocks to Buy. On August 7, William Blair retained its Buy rating on EPAM Systems, Inc. (NYSE:EPAM), with no price target on the stock. Maggie Nolan from William Blair kept her Buy rating on EPAM following strong Q2 FY2025 financial performance and strategic initiatives. The company posted revenue of around $1.35 billion, growing 18% year-over-year and exceeding estimates by $20.09 million. EPAM achieved its third consecutive quarter of positive organic growth during Q2, with a 5.3% organic revenue growth from a year ago. The company is expanding its market-leading position as an AI-native transformation company. With its AI-native revenue rising in double digits sequentially, Nolan believes that this will help EPAM secure new business opportunities. A close-up of a digital cloud, signifying the expansive reach of the software-as-a-service solution. The analyst is also optimistic about EPAM as the company expects its FY2025 year-over-year growth rate to be in the range of 13-15%. Whereas organic revenue is projected to grow between 3-5% in 2025. The positive outlook is backed by EPAM's continued organic growth and above-consensus guidance for Q3 FY2025. EPAM Systems, Inc. (NYSE:EPAM) is a provider of digital engineering, cloud, and AI-enabled transformation services. EPAM is also a business and experience consulting partner for international enterprises. While we acknowledge the potential of EPAM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
